A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to
Completed
Boehringer Ingelheim
Phase 3
2004-03-01
The primary objective of this trial is to compare the efficacy and safety of telmisartan 40
mg/hydrochlorothiazide 12.5mg (Micardis Plus) with that of losartan 50 mg/hydrochlorothiazide
12.5 mg, a reference AIIA combined with diuretic, in Taiwanese patients with mild to moderate
hypertension.
Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy
Completed
Boehringer Ingelheim
Phase 3
2005-01-01
The objective of this trial is to demonstrate that the fixed dose combination of telmisartan
40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan,
Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential
hypertension who fail to respond adequately to telmisartan monotherapy.
Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg
Completed
Boehringer Ingelheim
Phase 3
2005-04-01
To demonstrate that a fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg is
superior to telmisartan 80 mg alone in patients, who fail to respond adequately to
telmisartan 80 mg monotherapy, in lowering seated trough diastolic blood pressure after eight
weeks of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
